image

The best stocks to buy since 1993

Latest issue now available

Alliance Pharma - MHRA approves Diclectin for launch

July 2018

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • APH
  • Price:
  • 98p
My write up just two months ago was well timed with Alliance saying (earlier than I had expected it to) that the MHRA has approved its application for Diclectin, a prescription treatment for nausea in pregnancy.Alliance anticipates the UK launch in the autumn with other European territories in 2019. Management point towards peak sales of £40m.Separately, Alliance has also agreed to buy the exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand in the Asia-Pacific region from J&J for £60m. To fund the deal it placed 37.4m new shares to raise c.£32.1m after expenses whilst taking on c.£27.9m in debt.The Nizoral rights cover 15 countries including Japan, Thailand, South Ko ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

LIMITED PERIOD OFFER!

SUBSCRIBE TODAY AND SAVE £30 WITH OFFER CODE 30OFFSCSW

To access our archive of articles and to receive current issues you need to subscribe